Key Highlights
- Third-quarter Revenue was USD 40.6 million versus USD 38.4 million a year earlier, a rise of about 5.7% (calculated), led by instrument sales of USD 13.2 million.
- GAAP net loss was USD 37.8 million, or USD 0.12 per share, compared with USD 38.0 million, or USD 0.13, while the non-GAAP loss narrowed to USD 0.11 per share from USD 0.12.
- Cash, cash equivalents and investments ended the quarter at USD 199.4 million, down from USD 298.7 million a year earlier, according to the company release.
- PacBio now expects full-year 2026 revenue of USD 155 million to USD 160 million, and non-GAAP gross Margin fell to 36% from 42% on memory and Vega transition costs.
Instruments Lift PacBio (NASDAQ:PACB) Revenue While Consumables Slip
PacBio (NASDAQ:PACB) announced third-quarter 2026 results on November 4, 2026, for the quarter ended September 30. Revenue of USD 40.6 million split into USD 20.8 million of consumables, USD 13.2 million of instruments and USD 6.6 million of service and other. Consumables edged down from USD 21.3 million, and instruments rose from USD 11.3 million. The company, which makes HiFi long-read sequencing systems, placed 15 Revio systems versus 13 and 35 Vega systems versus 32, with more than 90% of Vega going to new customers. Annualized Revio pull-through per system fell to about USD 204,000 from about USD 236,000.
Margin Squeeze, Narrower Losses and a Shrinking Cash Balance
GAAP gross margin was 33% against 41%, and non-GAAP gross margin was 36% against 42%, which the company tied to higher memory costs and Vega Manufacturing transition costs. GAAP operating expenses fell to USD 50.5 million from USD 54.8 million, and non-GAAP operating expenses fell to USD 47.0 million from USD 53.9 million on restructuring savings. The non-GAAP net loss was USD 32.8 million versus USD 36.8 million. Cash and investments of USD 199.4 million compare with USD 298.7 million a year earlier, a gap of about USD 99.3 million (calculated), so funding runway remains a point to monitor.
SPRQ-Nx Adoption, New Partnerships and a CFO Change
Management said over half of Revio consumables revenue was tied to the SPRQ-Nx chemistry by quarter end, and two-thirds of the Revio installed base had opted to upgrade software to use it. The company also announced collaborations with GeneDx, Verily Health and TychoBio, and a Department of Veterans Affairs contract awarded to a customer, Sampled. Jim Gibson stepped down as Chief Financial Officer, and Mark Van Oene, President and Chief Executive Officer, was named interim CFO while a search proceeds, with Bill Meyer named Chief Accounting Officer. The release did not give the prior revenue outlook, so the size of any change in the new range is not stated.
Where Things Stand
USD 199.4 million of cash gives PacBio (NASDAQ:PACB) room to keep investing, but the balance has dropped by about USD 99.3 million (calculated) in a year while the company still loses roughly USD 0.12 a share. Revenue grew and expenses fell, yet gross margin compressed and consumable revenue declined. Whether the SPRQ-Nx upgrade cycle lifts pull-through, how the memory cost pressure evolves, and who becomes permanent CFO are the next markers, along with execution against the USD 155 million to USD 160 million revenue range.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...